Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook and Forecast

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Published Date : 2023-05-11

Updated On : 2024-02-21

Pages : 161

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook

Thelansis’s “Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

Head and neck squamous cell carcinoma (HNSCC) presents a multifaceted challenge for clinicians due to its complexity. Recent understanding attributes human papillomavirus (HPV) infection as the primary cause, particularly in oropharyngeal squamous cell carcinoma (OPSCC), which constitutes approximately 60–70% of cases. While the majority of HNSCC patients are diagnosed at a stage amenable to definitive therapy, about 10% present with distant metastases. Notably, a significant portion of patients, particularly those with HPV-negative HNSCC, experience recurrence. Unfortunately, recurrent or metastatic HNSCC carries a bleak prognosis, with median survival ranging from 12 to 15 months despite treatment efforts. The standard approach involves a multidisciplinary strategy incorporating surgery, chemotherapy, and radiotherapy, primarily targeted towards locally advanced diseases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages:
Linkedin Mini logo Thelansis Twitter Mini logoThelansis Facebook Mini logo

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Competitive Landscape

S. no Asset Company Stage
1 Ficlatuzumab and Cetuximab AVEO Pharmaceuticals, Inc. Phase 1/2
2 Lenvatinib + Pembrolizumab Merck Sharp & Dohme LLC Phase 2
3 Nivolumab Bristol-Myers Squibb Phase 2
4 Ramucirumab and Pembrolizumab Eli Lilly and Company Phase 2
5 RAD001 and Erlotinib Novartis Phase 2
6 NRC-2694-A and Paclitaxel NATCO Pharma Ltd. Phase 2
7 BNT113 and Pembrolizumab BioNTech SE Phase 2
8 Monalizumab and Cetuximab AstraZeneca Phase 1/2
9 ASP-1929 Rakuten Medical, Inc. Phase 1/2
10 ALKS 4230 Mural Oncology, Inc Phase 2

Continued...

KOLs across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

COUNTRY No. Of KOLs
USA 17
GERMANY 4
UK 4
SPAIN 3
FRANCE 2
ITALY 3
JAPAN 3
CHINA 4

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast

1.       Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) – Key Findings Summary

         1.1.    Clinical findings
                     1.1.1. Disease overview
                     1.1.2. Therapeutic practices
                     1.1.3. Future outlook
         1.2.    Commercial findings
                     1.2.1. Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) market scenario 2023
                     1.2.2. Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) market scenario 2028
                     1.2.3. Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) market scenario 2033

2.       Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

         2.1.    Disease Introduction
         2.2.    Pathophysiology
         2.3.    Signs and Symptoms
         2.4.    Risk Factors
         2.5.    Etiology
         2.6.    Classification
         2.7.    Pathogenesis
         2.8.    Diagnosis
         2.9.    Complications
         2.10. Treatment Algorithm
                     2.10.1.    Treatment in US (guidelines)
                     2.10.2.    Treatment in EU-5 (guidelines)
                     2.10.3.    Treatment in Japan (guidelines)
                     2.10.4.    Treatment in China (guidelines)
         2.11. Treatment Goals for Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
         2.12. Referral Patterns
                     2.12.1.    Referral Scenario in US
                     2.12.2.    Referral Scenario in EU-5
                     2.12.3.    Referral Scenario in Japan
                     2.12.4.    Referral Scenario in China
         2.13. Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Prognosis
         2.14. Healthcare burden
                     2.14.1.    Healthcare burden in US
                     2.14.2.    Healthcare burden in EU-5
                     2.14.3.    Healthcare burden in Japan
                     2.14.4.    Healthcare burden in China
         2.15.  Unmet Needs in Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) management
         2.16.  Market Opportunity for Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
         2.17. KOL Comments on current and upcoming/expected treatment practices in Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

3.       Epidemiology

         3.1.    Epidemiology Overview
         3.2.    Epidemiology by Geography
                     3.2.1.  Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology in US (2023-2033)
                             3.2.1.1.              Incidence of Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
                             3.2.1.2.              Diagnosed cases
                             3.2.1.3.              Treatable Patient Pool
                             3.2.1.4.              Epidemiology Trends
                     3.2.2.  Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology in EU-5 (2023-2033)
                             3.2.2.1.              Incidence of Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
                             3.2.2.2.              Diagnosed cases
                             3.2.2.3.              Treatable Patient Pool
                             3.2.2.4.              Epidemiology Trends
                     3.2.3.  Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology in Japan (2023-2033)
                             3.2.3.1.              Incidence of Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
                             3.2.3.2.              Diagnosed cases
                             3.2.3.3.              Treatable Patient Pool
                             3.2.3.4.              Epidemiology Trends
                     3.2.4.  Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology in China (2023-2033)
                             3.2.4.1.              Incidence of Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
                             3.2.4.2.              Diagnosed cases
                             3.2.4.3.              Treatable Patient Pool
                             3.2.4.4.              Epidemiology Trends
         3.3.    Epidemiology Trends (World-wide)

4.       Market Outlook

         4.1.    US Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.1.1. Market Progression (Futuristic)
                     4.1.2. Market Trends and Expectations
                             4.1.2.1.              Worst case scenario
                             4.1.2.2.              Base Case Scenario
                             4.1.2.3.              Best Case Scenario
                     4.1.3. Drivers and Barriers
         4.2.    UK Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.2.1. Market Progression (Futuristic)
                     4.2.2. Market Trends and Expectations
                             4.2.2.1.              Worst case scenario
                             4.2.2.2.              Base Case Scenario
                             4.2.2.3.              Best Case Scenario
                     4.2.3. Drivers and Barriers
         4.3.    France Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.3.1. Market Progression (Futuristic)
                     4.3.2. Market Trends and Expectations
                             4.3.2.1.              Worst case scenario
                             4.3.2.2.              Base Case Scenario
                             4.3.2.3.              Best Case Scenario
                     4.3.3. Drivers and Barriers
         4.4.    Germany Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.4.1. Market Progression (Futuristic)
                     4.4.2. Market Trends and Expectations
                             4.4.2.1.              Worst case scenario
                             4.4.2.2.              Base Case Scenario
                             4.4.2.3.              Best Case Scenario
                     4.4.3. Drivers and Barriers
         4.5.    Italy Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.5.1. Market Progression (Futuristic)
                     4.5.2. Market Trends and Expectations
                             4.5.2.1.              Worst case scenario
                             4.5.2.2.              Base Case Scenario
                             4.5.2.3.              Best Case Scenario
                     4.5.3. Drivers and Barriers
         4.6.    Spain Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.6.1. Market Progression (Futuristic)
                     4.6.2. Market Trends and Expectations
                             4.6.2.1.              Worst case scenario
                             4.6.2.2.              Base Case Scenario
                             4.6.2.3.              Best Case Scenario
                     4.6.3. Drivers and Barriers
         4.7.    Japan Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.7.1. Market Progression (Futuristic)
                     4.7.2. Market Trends and Expectations
                             4.7.2.1.              Worst case scenario
                             4.7.2.2.              Base Case Scenario
                             4.7.2.3.              Best Case Scenario
                     4.7.3. Drivers and Barriers
         4.8.    China Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast 2023-2033
                     4.8.1. Market Progression (Futuristic)
                     4.8.2. Market Trends and Expectations
                             4.8.2.1.              Worst case scenario
                             4.8.2.2.              Base Case Scenario
                             4.8.2.3.              Best Case Scenario
                     4.8.3. Drivers and Barriers
         4.9.    Key Expected Milestones (world-wide) Impacting the Market

5.       Competitive Landscape

         5.1.    Pipeline Therapies Overview
                     5.1.1. Phase III Therapies
                                      5.1.1.1.                     Current Status
                                      5.1.1.2.                     Trial details, results
                                      5.1.1.3.                     Approval Timeline
                                      5.1.1.4.                     Likelihood of approval
                                      5.1.1.5.                     Expected Product Positioning
                             5.1.1.2.              All other Phase III Therapies …..
                             5.1.1.3.              Attribute Analysis of Phase III molecules
                     5.1.2.  Phase II and Phase I/II Therapies
                                      5.1.2.1.                     Current Status
                                      5.1.2.2.                     Trial details, results
                                      5.1.2.3.                     Approval Timelines
                     5.1.3. List of active Pre-clinical Therapies
                                      5.1.3.1.                     Status in Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
                                      5.1.3.2.                     Company positioning
                             5.1.3.2.              All other pre-clinical therapies
                     5.1.4. List of Inactive/discontinued assets
                             5.1.4.1.              Business impact of discontinuations on current pipeline
                     5.1.5. Potential winners from Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Pipeline
                             5.1.5.1.              Potential Blockbusters across the pipeline

6.       Regulatory/Approval Scenario

         6.1.    Regulatory/Approval Framework in US
                     6.1.1. Policy Framework
                     6.1.2. Payer Expectations
         6.2.    Regulatory/Approval Framework in UK
                     6.2.1. Policy Framework
                     6.2.2. Payer Expectations
         6.3.    Regulatory/Approval Framework in France
                     6.3.1. Policy Framework
                     6.3.2. Payer Expectations
         6.4.    Regulatory/Approval Framework in Germany
                     6.4.1. Policy Framework
                     6.4.2. Payer Expectations
         6.5.    Regulatory/Approval Framework in Italy
                     6.5.1. Policy Framework
                     6.5.2. Payer Expectations
         6.6.    Regulatory/Approval Framework in Spain
                     6.6.1. Policy Framework
                     6.6.2. Payer Expectations
         6.7.       Regulatory/Approval Framework in Japan
                     6.7.1. Policy Framework
                     6.7.2. Payer Expectations
         6.8.       Regulatory/Approval Framework in China
                     6.8.1. Policy Framework
                     6.8.2. Payer Expectations

7.       Clinical Trial Assessment – Current and Future Paradigm

         7.1.    Distribution of Primary Endpoints across trials
         7.2.    Distribution of Secondary Endpoints across trials
         7.3.    Evolution and acceptance of surrogate endpoints
         7.4.    Key Investigator initiated trials
         7.5.    Attrition analysis
                     7.5.1. Suspended/Discontinued Assets
                     7.5.2. Failed Trials, Reasons and Business Impact
                     7.5.3. Terminated Trials, Reasons and Business Impact
                     7.5.4. Withdrawn Trials, Reasons and Business Impact
         7.6.    Trial enrollment scenario and challenges
         7.7.    Clinical Trial Guidance (across geographies)

8.       Thelansis Commentary

         8.1.    Key Unmet needs in Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
         8.2.    Possible Best-case Clinical Trial Strategies
         8.3.    Possible Best Case Targeted Product Profile (TPP)
         8.4.    Possible Best-case Market positioning strategies
         8.5.    Possible Best-case Market Access Strategies
         8.6.    Possible Best-case LCM Strategies
         8.7.    Overall View on Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market in Dollar Value

9.       Report Methodology

         9.1.    Secondary research
         9.2.    Primary research
         9.3.    Data collation
         9.4.    Insight Generation

10.   About Thelansis

         10.1.    Our Capabilities
         10.2.    Our Services
         10.3.    Our Contacts
         10.4.    Disclaimer